Celldex Therapeutics (CLDX) Current Assets (2010 - 2026)

Celldex Therapeutics' Current Assets history runs 17 years deep, the most recent figure standing at $459.2 million for Q1 2026.

• On a quarterly basis, Current Assets fell 33.81% year-over-year to $459.2 million in Q1 2026; TTM through Mar 2026 was $459.2 million, a 33.81% decrease from a year earlier, with the FY2025 full-year figure at $534.7 million, down 28.44% from the prior year.
• Current Assets retreated to $459.2 million in Q1 2026 per CLDX's latest filing, from $534.7 million in the prior quarter.
• Across five years, Current Assets topped out at $835.3 million in Q1 2024 and bottomed at $245.9 million in Q3 2023.
• The 5-year median for Current Assets is $459.2 million (2026), against an average of $515.1 million.
• Across the five-year window, Current Assets soared 216.69% in 2024 and tumbled 33.81% in 2026, its largest moves.
• Year by year, Current Assets stood at $317.7 million in 2022, then jumped by 35.88% to $431.7 million in 2023, then soared by 73.08% to $747.2 million in 2024, then dropped by 28.44% to $534.7 million in 2025, then retreated by 14.11% to $459.2 million in 2026.
• Per Business Quant, the three latest CLDX Current Assets figures stand at $459.2 million (Q1 2026), $534.7 million (Q4 2025), and $604.3 million (Q3 2025).